Marksans Pharma Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Mark Saldanha
Chief executive officer
₹64.1m
Total compensation
| CEO salary percentage | 74.84% |
| CEO tenure | 10.9yrs |
| CEO ownership | 43.8% |
| Management average tenure | 12yrs |
| Board average tenure | 7.4yrs |
Recent management updates
Recent updates
Narrative Update • Sep 03
MARKSANS: Dividend Payout And Acquisition Plans Will Shape Measured Future Share Rerating
Analysts have lifted their fair value estimate for Marksans Pharma from about ₹266 to around ₹324, citing updated assumptions on discount rates, revenue growth, profit margins and future P/E multiples. What’s in the News for Marksans Pharma Shareholders of Marksans Pharma approved a final dividend of ₹0.90 per equity share with a face value of ₹1 for the financial year ended 31 March 2026 at the annual general meeting held on 27 August 2026.Analysis Article • Aug 15
Marksans Pharma Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
The investors in Marksans Pharma Limited 's ( NSE:MARKSANS ) will be rubbing their hands together with glee today...
Narrative Update • Aug 14
MARKSANS: Higher Margin Outlook And Dividend Plans Will Support Upside Potential
The analyst price target for Marksans Pharma has been revised from ₹298 to ₹385, with analysts pointing to updated assumptions for discount rates, revenue growth, profit margins, and future P/E as the key drivers of this change. What’s in the News for Marksans Pharma A board meeting is scheduled on 12 August 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter ended 30 June 2026.Narrative Update • Jun 23
MARKSANS: Dividend Decision And Stable Assumptions Will Shape Measured Future Share Rerating
Analysts have kept their Marksans Pharma fair value estimate broadly unchanged at ₹266. This reflects consistent assumptions on discount rate, revenue growth, profit margin, and future P/E in their latest price target update.New Narrative • Jun 15
Unused Capacity And Regulated Market Expansion Will Drive A Stronger Future Margin Profile
Catalysts About Marksans Pharma Marksans Pharma is a global pharmaceuticals company focused on generic formulations across regulated markets including the U.S., U.K., Europe, Australia, New Zealand and select other regions. What are the underlying business or industry changes driving this perspective?Narrative Update • Jun 04
MARKSANS: Upcoming Dividend Decision Will Support Positive Share Price Rerating
Analysts have lifted the Marksans Pharma price target from ₹216.67 to ₹266.00, citing updated assumptions for revenue growth, profit margins, a slightly lower discount rate, and an adjusted future P/E input. What's in the News A board meeting was held on May 26, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
New Narrative • Jun 01
Rising North America Dependence And Overextended Pipeline Will Pressure Margins And Earnings
Catalysts About Marksans Pharma Marksans Pharma is a global pharmaceutical company focused on generic formulations across regulated markets including North America, the U.K., Europe, Australia and New Zealand. What are the underlying business or industry changes driving this perspective?Analysis Article • May 29
Earnings Beat: Marksans Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Marksans Pharma Limited ( NSE:MARKSANS ) defied analyst predictions to release its full-year results, which were ahead...Analysis Article • May 28
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analysis Article • Feb 10
Marksans Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
It's been a pretty great week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, with its shares surging 13% to...Analysis Article • Jan 15
Marksans Pharma Limited's (NSE:MARKSANS) Shares May Have Run Too Fast Too Soon
It's not a stretch to say that Marksans Pharma Limited's ( NSE:MARKSANS ) price-to-earnings (or "P/E") ratio of 22.2x...Analysis Article • Dec 09
Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Nov 17
Analysts Have Made A Financial Statement On Marksans Pharma Limited's (NSE:MARKSANS) Second-Quarter Report
It's been a good week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, because the company has just released...Narrative Update • Nov 11
MARKSANS: Upcoming Board Meeting And UK Regulatory Success Will Drive Momentum
Analysts have reduced their price target for Marksans Pharma from ₹231.67 to ₹216.67. They cite slight increases in the discount rate and a modest drop in the company's projected future price-to-earnings ratio as reasons for the adjustment.Analysis Article • Oct 15
Here's Why We Think Marksans Pharma (NSE:MARKSANS) Might Deserve Your Attention Today
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Narrative Update • Aug 15
Developed Markets Will Support Affordable Generic Expansion
Marksans Pharma's consensus price target has been revised downward, primarily due to sharply reduced revenue growth forecasts and a decline in net profit margin, lowering the fair value estimate from ₹301.00 to ₹231.67. What's in the News Board re-appointed Mr. Mark Saldanha as Managing Director, subject to shareholder approval at the upcoming AGM.Analysis Article • Aug 15
Marksans Pharma Limited (NSE:MARKSANS) Analysts Are Reducing Their Forecasts For This Year
NSEI:MARKSANS 1 Year Share Price vs Fair Value Explore Marksans Pharma's Fair Values from the Community and select...Analysis Article • Aug 07
Marksans Pharma Limited (NSE:MARKSANS) Doing What It Can To Lift Shares
NSEI:MARKSANS 1 Year Share Price vs Fair Value Explore Marksans Pharma's Fair Values from the Community and select...Analysis Article • Jun 28
Calculating The Intrinsic Value Of Marksans Pharma Limited (NSE:MARKSANS)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Marksans Pharma fair value estimate is ₹239 With ₹253 share...Analysis Article • May 27
We Think That There Are Some Issues For Marksans Pharma (NSE:MARKSANS) Beyond Its Promising Earnings
Marksans Pharma Limited's ( NSE:MARKSANS ) robust recent earnings didn't do much to move the stock. However the...Analysis Article • May 22
₹299: That's What Analysts Think Marksans Pharma Limited (NSE:MARKSANS) Is Worth After Its Latest Results
It's been a good week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, because the company has just released...Analysis Article • May 14
Should You Be Adding Marksans Pharma (NSE:MARKSANS) To Your Watchlist Today?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analysis Article • Mar 23
Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Mar 05
Marksans Pharma Limited's (NSE:MARKSANS) P/E Is On The Mark
It's not a stretch to say that Marksans Pharma Limited's ( NSE:MARKSANS ) price-to-earnings (or "P/E") ratio of 24.6x...Analysis Article • Feb 15
Marksans Pharma Limited (NSE:MARKSANS) Just Reported Earnings, And Analysts Cut Their Target Price
It's been a mediocre week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, with the stock dropping 15% to...Analysis Article • Feb 01
Is Marksans Pharma Limited (NSE:MARKSANS) Expensive For A Reason? A Look At Its Intrinsic Value
Key Insights Marksans Pharma's estimated fair value is ₹190 based on 2 Stage Free Cash Flow to Equity Marksans Pharma's...
New Narrative • Jan 28
Teva Pharma Facility And US Expansion To Strengthen Future Outlook
Strategic growth in the U.S. market and facility expansion bolster revenue growth, earnings, and profit margins through enhanced capacity and market share.Analysis Article • Nov 27
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Despite an already strong run, Marksans Pharma Limited ( NSE:MARKSANS ) shares have been powering on, with a gain of...Analysis Article • Oct 24
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analysis Article • Sep 21
Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking
Marksans Pharma Limited ( NSE:MARKSANS ) shares have continued their recent momentum with a 45% gain in the last month...Analysis Article • Jul 28
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company
Marksans Pharma Limited ( NSE:MARKSANS ) shareholders would be excited to see that the share price has had a great...Analysis Article • Jun 07
Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
The market shrugged off Marksans Pharma Limited's ( NSE:MARKSANS ) solid earnings report. We did some digging and...Analysis Article • May 31
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analysis Article • Feb 16
Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
When close to half the companies in India have price-to-earnings ratios (or "P/E's") above 32x, you may consider...Analysis Article • Jan 26
Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analysis Article • Dec 02
We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | ₹5b |
| Mar 31 2026 | ₹64m | ₹48m | ₹4b |
| Dec 31 2025 | n/a | n/a | ₹4b |
| Sep 30 2025 | n/a | n/a | ₹4b |
| Jun 30 2025 | n/a | n/a | ₹4b |
| Mar 31 2025 | ₹64m | ₹48m | ₹4b |
| Dec 31 2024 | n/a | n/a | ₹4b |
| Sep 30 2024 | n/a | n/a | ₹3b |
| Jun 30 2024 | n/a | n/a | ₹3b |
| Mar 31 2024 | ₹69m | ₹48m | ₹3b |
| Dec 31 2023 | n/a | n/a | ₹3b |
| Sep 30 2023 | n/a | n/a | ₹3b |
| Jun 30 2023 | n/a | n/a | ₹3b |
| Mar 31 2023 | ₹52m | ₹48m | ₹3b |
| Dec 31 2022 | n/a | n/a | ₹2b |
| Sep 30 2022 | n/a | n/a | ₹2b |
| Jun 30 2022 | n/a | n/a | ₹2b |
| Mar 31 2022 | ₹38m | ₹35m | ₹2b |
| Dec 31 2021 | n/a | n/a | ₹2b |
| Sep 30 2021 | n/a | n/a | ₹2b |
| Jun 30 2021 | n/a | n/a | ₹3b |
| Mar 31 2021 | ₹10m | ₹10m | ₹2b |
| Dec 31 2020 | n/a | n/a | ₹2b |
| Sep 30 2020 | n/a | n/a | ₹2b |
| Jun 30 2020 | n/a | n/a | ₹1b |
| Mar 31 2020 | ₹10m | ₹10m | ₹1b |
Compensation vs Market: Mark's total compensation ($USD669.48K) is above average for companies of similar size in the Indian market ($USD492.16K).
Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.
CEO
Mark Saldanha (54 yo)
10.9yrs
Tenure
₹64,132,682
Compensation
Mr. Mark B. Saldanha, M.Sc. (Maths) & (Stat.)., Dip. (Fin. Mgt.) serves as Promoter and Managing Director of Marksans Pharma Limited, which he joined in October 6, 2005 (alternate name, Glenmark Laboratori...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Non-Independent Executive Chairman & MD | no data | ₹64.13m | 43.8% ₹ 63.5b | |
| Group Chief Financial Officer | 24yrs | ₹19.67m | no data | |
| Company Secretary | 17.6yrs | ₹3.09m | no data | |
| Whole-Time Executive Non Independent Director | 12yrs | ₹7.07m | 0.073% ₹ 105.8m | |
| Whole-Time Executive Non Independent Director | 7.7yrs | ₹26.32m | no data | |
| Director Operations | no data | ₹5.80m | no data | |
| Managing Director of Australia Operations | no data | no data | no data | |
| Senior Vice President of QC | no data | ₹10.61m | no data | |
| Managing Director of UK Operations | no data | no data | no data | |
| Chief Operating Officer of US Operations | no data | ₹10.29m | no data | |
| Chief Executive Officer of EU Operations | 1.7yrs | no data | no data |
12.0yrs
Average Tenure
56.5yo
Average Age
Experienced Management: MARKSANS's management team is seasoned and experienced (12 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Non-Independent Executive Chairman & MD | 10.9yrs | ₹64.13m | 43.8% ₹ 63.5b | |
| Whole-Time Executive Non Independent Director | 12yrs | ₹7.07m | 0.073% ₹ 105.8m | |
| Whole-Time Executive Non Independent Director | 7.7yrs | ₹26.32m | no data | |
| Non-Executive & Non-Independent Director | 5.1yrs | no data | no data | |
| Non-Executive & Independent Director | 7.2yrs | ₹310.00k | no data | |
| Non-Executive Independent Director | 8.5yrs | ₹500.00k | no data | |
| Non-Executive & Independent Director | 3.3yrs | ₹500.00k | no data | |
| Independent Director | 1.4yrs | ₹400.00k | no data |
7.4yrs
Average Tenure
55yo
Average Age
Experienced Board: MARKSANS's board of directors are considered experienced (7.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/21 14:55 |
| End of Day Share Price | 2026/09/21 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Marksans Pharma Limited is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ranjit Kapadia | Centrum Broking Limited |
| Maitri Sheth | Choice Equity Broking Private Limited |
| Nitin Agarwal | DAM Capital Advisors |